Our comprehensive Epilepsy Program delivers world-class care for epilepsy patients with state-of-the-art techniques and treatment approaches. U of U Health is one of only a few medical centers in the ...

NTRA’s oncology franchise, led by Signatera MRD testing, is the main bull case at this point. As long as they keep building on their testing volumes, I believe this should support a long runway in ...

Scientists have discovered a novel low-cost method of testing for cancers. Called the Heatrich-BS assay, this new test sequences clinical samples that have been heated in order to isolate ...

Liquid biopsies—tests that detect circulating tumor cellular components in the bloodstream—have the potential to transform cancer by reducing health inequities in screening, diagnostics, and ...

Delfi Diagnostics has put forward a new cancer monitoring test that searches the blood for broken pieces of tumor DNA, and it is kicking off the test’s launch with a collaboration with Immunocore to ...

Cancer continues to be a leading cause of mortality worldwide, highlighting the urgent need to develop more advanced, efficient, and early detection methods. Addressing this critical need, City ...

C2i Genomics, a New York, NY-based cancer intelligence company, launched its C2inform minimal residual disease (MRD) test across Europe after snagging CE-IVD marking in the European Union, the United ...

Three at-home vision-monitoring tools failed to detect worsening neovascular age-related macular degeneration (AMD), a diagnostic-test accuracy study reported. The paper-based KeepSight Journal from ...